Global /South Korea /Healthcare /Biotechnology /461030

IMB Dx, Inc.

461030

• KRX: 461030 • Delayed

6,960KRW -2.7%

4.61 USD

As of 18 June 2026, IMB Dx, Inc. has a market cap of $65.71M USD, ranking #28539 globally and #1532 in South Korea. It ranks #2588 in the Healthcare sector, and #502 in the Biotechnology industry.

Global Rank

28539

Country Rank

1532

Sector Rank

2588

Industry Rank

502

Key Stats

Market Cap

$65.71MUSD

100.23B KRW

Enterprise Value

$53.0MUSD

79.99B KRW

Revenue (TTM)

$3.49MUSD

5.33B KRW

EBITDA (TTM)

-$4.79MUSD

-7.23B KRW

Net Income (TTM)

-$5.2MUSD

-7.93B KRW

EBITDA Margin

-136%

Profit Margin

-149%

PS Ratio

18.8

PB Ratio

4.0

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Biotechnology

CEO

Tae-You Kim open_in_new

Founded

2018

Website

imbdx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.7%	-1%	5.7%	-26%	-36%	-29%	-23%	-85%	-85%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	461030 IMBdx Inc ISIN: KR7461030009 Shares Out.: Shares Outstanding: 14.335M¹ Shares Float: 7.036M² TV: TradingView: KRX: 461030 SA: Stock Analysis: KRX: 461030 YF: Yahoo Finance: 461030.KS GF: Google Finance: KRX: 461030 BA: Barron's: 461030 MS: Morningstar: XKRX: 461030	6,960 KRW	TV: TradingView: KRX: 461030 SA: Stock Analysis: KRX: 461030 YF: Yahoo Finance: 461030.KS GF: Google Finance: KRX: 461030 BA: Barron's: 461030 MS: Morningstar: XKRX: 461030

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About IMB Dx, Inc.

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; AlphaLiquid HRR for diagnostics of targeted therapies, utilizing liquid biopsy profiling technology; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection. IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.

Similar Companies

Industry: Biotechnology (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Biologics Co.,Ltd. KRX: 207940	$44.7B 68.19T KRW 68K%	35.5	South Korea
Celltrion, Inc. KRX: 068270	$28.03B 42.76T KRW 43K%	43.8	South Korea
ALTEOGEN Inc. KRX: 196170	$13.33B 20.33T KRW 20K%	146.6	South Korea
HLB Co., Ltd. KRX: 028300	$5.49B 8.37T KRW 8K%	-	South Korea
Peptron, Inc. KRX: 087010	$3.98B 6.07T KRW 6K%	-	South Korea
SK bioscience Co.,Ltd. KRX: 302440	$2.25B 3.42T KRW 3K%	-	South Korea

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 278K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 243K%	19.0	United States
argenx SE EBR: ARGX	$47.76B 41.39B EUR 73K%	39.9	Netherlands
CSL Ltd. ASX: CSL	$42.44B 60.27B AUD 64K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.29B 33.71B CHF 64K%	37.2	Switzerland
Natera, Inc. NASDAQ: NTRA	$27.6B 42K%	-	United States

chevron_leftBack